Cybin to Present at Upcoming Cantor and Benzinga Investor Conferences TORONTO, CANADA

Cybin to Present at Upcoming Cantor and Benzinga Investor Conferences

TORONTO, CANADA September 27, 2021 Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ( Cybin

or the Company ), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting virtually at two upcoming investor conferences as follows:

Cantor Virtual Global Healthcare Conference, Fireside Chat:

The presentation will be webcast live using the link above, and a replay will be available for 90 days.

Benzinga Healthcare Small Cap Conference, Presentation and Panel Discussion:

Immediately following the presentation, Mr. Drysdale will participate on a panel, Addressing Mental Health

through Emerging Therapies, at 12:35PM ET. Both the presentation and panel discussion will be webcast live using the link above.

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug

delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

Cautionary Notes and Forward-Looking Statements

Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking

statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results

expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as may , should , could , intend , estimate ,

plan , anticipate , expect , believe or continue , or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding enhanced

liquidity, the value of additional capital markets exposure, access to institutional and retail investors, the Company s new strategic brand messaging campaign, and psychedelic drug development programs to potentially treat mental health

disorders. There are numerous risks and uncertainties that could cause actual results and Cybin s plans and objectives to differ materially from those expressed in the forward-looking information. Actual results and future events could differ

materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety

by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

Cybin makes no medical, treatment or

health benefit claims about Cybin s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives

or other psychedelic compounds or nutraceutical products. The efficacy of such products have not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other

psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any

references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to

commercialize its business, it may have a material adverse effect on Cybin s performance and operations.

The NEO Exchange has neither approved

nor disapproved the contents of this news release and is not responsible for the adequacy and accuracy of the contents herein.

Tim Regan/Scott Eckstein

KCSA Strategic Communications

In-Site Communications, Inc.